Stock 688293 SHANGHAI OPM BIOSCIENCES CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Shanghai OPM Biosciences Co., Ltd.

Equities

688293

CNE100005PF1

Pharmaceuticals

End-of-day quote Shanghai S.E.
Other stock markets
 03:30:00 31/05/2024 am IST 		5-day change 1st Jan Change
37.71 CNY +6.65% Intraday chart for Shanghai OPM Biosciences Co., Ltd. +5.96% -31.65%
09/05 OPM Biosciences' Shareholder to Cut Stake MT
29/04 Shanghai OPM Biosciences Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Valuation

Fiscal Period: December 2022 2023 2024 2025 2026
Capitalization 1 8,460 6,332 4,296 - -
Enterprise Value (EV) 1 8,460 6,332 4,296 4,296 4,296
P/E ratio 47.9 x 117 x 48.6 x 28.2 x 19.7 x
Yield - 0.42% 0.88% 1.96% 3.87%
Capitalization / Revenue - 26 x 12.7 x 8.75 x 6.44 x
EV / Revenue - 26 x 12.7 x 8.75 x 6.44 x
EV / EBITDA - 66.2 x 28.2 x 17.8 x 13.9 x
EV / FCF - -323 x 102 x -1,432 x 65.1 x
FCF Yield - -0.31% 0.98% -0.07% 1.54%
Price to Book - 2.93 x 1.96 x 1.87 x 1.84 x
Nbr of stocks (in thousands) 1,14,772 1,14,772 1,13,914 - -
Reference price 2 73.71 55.17 37.71 37.71 37.71
Announcement Date 23/02/23 27/02/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2022 2023 2024 2025 2026
Net sales 1 - 243.1 339.5 491 667
EBITDA 1 - 95.71 152.5 241.5 308
EBIT 1 - 61.81 99.33 173 251.5
Operating Margin - 25.42% 29.26% 35.23% 37.7%
Earnings before Tax (EBT) 1 - 61.67 101.3 174.7 252.5
Net income 1 105.4 54.04 88.73 153.6 219.6
Net margin - 22.23% 26.14% 31.28% 32.92%
EPS 2 1.540 0.4700 0.7767 1.337 1.915
Free Cash Flow 1 - -19.59 42 -3 66
FCF margin - -8.06% 12.37% -0.61% 9.89%
FCF Conversion (EBITDA) - - 27.54% - 21.43%
FCF Conversion (Net income) - - 47.33% - 30.05%
Dividend per Share 2 - 0.2300 0.3300 0.7400 1.460
Announcement Date 23/02/23 27/02/24 - - -
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2022 2023 2024 2025 2026
Net Debt - - - - -
Net Cash position - - - - -
Leverage (Debt/EBITDA) - - - - -
Free Cash Flow 1 - -19.6 42 -3 66
ROE (net income / shareholders' equity) - 2.48% 4.13% 6.57% 9.35%
ROA (Net income/ Total Assets) - - 4.2% 6.6% -
Assets 1 - - 2,113 2,327 -
Book Value Per Share 2 - 18.80 19.30 20.20 20.50
Cash Flow per Share 2 - 0.5000 0.4400 1.950 -
Capex 1 - 77.5 88 90 67.5
Capex / Sales - 31.9% 25.92% 18.33% 10.12%
Announcement Date 23/02/23 27/02/24 - - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Shanghai OPM Biosciences Co., Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
37.71 CNY
Average target price
58.66 CNY
Spread / Average Target
+55.56%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
SHANGHAI OPM BIOSCIENCES CO., LTD. Stock Shanghai OPM Biosciences Co., Ltd.
-31.65% 593M
CSL LIMITED Stock CSL Limited
-2.29% 89.87B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
-3.95% 37.57B
BIOGEN INC. Stock Biogen Inc.
-13.07% 32.75B
UCB Stock UCB
+63.05% 26.47B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-22.14% 14.25B
INCYTE CORPORATION Stock Incyte Corporation
-7.96% 12.99B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-9.33% 11.93B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-46.33% 10.84B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+5.77% 9.11B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. 688293 Stock
  4. Financials Shanghai OPM Biosciences Co., Ltd.